Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2′,3,5′,6-pentachlorobiphenyl (PCB 95)
- 1 July 2007
- journal article
- Published by Elsevier in NeuroToxicology
- Vol. 28 (4) , 770-779
- https://doi.org/10.1016/j.neuro.2006.08.007
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Pharmacologic and Functional Characterization of Malignant Hyperthermia in the R163C RyR1 Knock-in MouseAnesthesiology, 2006
- Heat‐ and anesthesia‐induced malignant hyperthermia in an RyR1 knock‐in mouseThe FASEB Journal, 2005
- Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibilityEuropean Journal of Anaesthesiology, 2003
- Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibilityEuropean Journal of Anaesthesiology, 2003
- Maurocalcine and Peptide A Stabilize Distinct Subconductance States of Ryanodine Receptor Type 1, Revealing a Proportional Gating MechanismJournal of Biological Chemistry, 2003
- Identification of functional type 1 ryanodine receptors in mouse dendritic cellsFEBS Letters, 2002
- Regulation of mammalian ryanodine receptorsFrontiers in Bioscience-Landmark, 2002
- Primary structure and distribution of a novel ryanodine receptor/calcium release channel from rabbit brainFEBS Letters, 1992
- Primary structure and functional expression from cDN A of the cardiac ryanodine receptor/calcium release channelFEBS Letters, 1990
- Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermiaNature, 1990